LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)Jiahong Dong, M. Kudo, M. Zhao et al.|Annals of Oncology|2025Cited by 37
Launch of the International Living Donor Liver Transplantation Outcomes RegistrySebastian M. Staubli, Nancy L. Ascher, Alexander Steen Grover et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 21
uniLIVER: a human liver cell atlas for data-driven cellular state mappingYanhong Wu, Jin Gu, Yuhan Fan et al.|Journal of genetics and genomics/Journal of Genetics and Genomics|2025Cited by 4